Physician profile
Michele Novella
NPI 1750307948
$330,558.96
in general payments reported to CMS, 2019-2025
33 companies · $134K in 2025
The $134K reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $7,229 · 2022: $15K · 2023: $38K · 2024: $136K · 2025: $134K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $84K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $75K · Travel and Lodging: $64K · Honoraria: $62K · Food and Beverage: $17K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $5,309 · Education: $178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $83,527.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $75,404.00 |
| Travel and Lodging | $64,237.70 |
| Honoraria | $61,900.00 |
| Food and Beverage | $17,292.02 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $5,308.57 |
| Education | $178.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $151,708.41 | 2022-2025 | Auvelity, Sunosi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $105,029.97 | 2021-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $25,130.31 | 2024-2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $11,640.50 | 2021-2025 | Trintellix, Entyvio |
| Alkermes, INC. | $7,049.90 | 2021-2025 | Lybalvi, Aristada, Vivitrol |
| Biogen, INC. | $6,323.67 | 2023 | |
| Vertical Pharmaceuticals, LLC | $5,330.42 | 2025 | Relexxii |
| Alfasigma USA, INC. | $5,251.47 | 2021-2022 | |
| Abbvie INC. | $3,118.01 | 2021-2025 | |
| Sage Therapeutics, LLC | $2,430.00 | 2024 | |
| Corium, LLC | $2,262.83 | 2022-2025 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $1,017.15 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Neurocrine Biosciences, INC. | $477.76 | 2021-2025 | Ingrezza |
| Bausch Health US, LLC | $454.89 | 2021-2025 | Wellbutrin, Aplenzin |
| Janssen Pharmaceuticals, INC | $382.40 | 2021-2025 | Invega Sustenna, Spravato, Invega Trinza |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $346.23 | 2021-2024 | Jornay Pm |
| Vanda Pharmaceuticals INC. | $345.58 | 2021-2025 | Fanapt |
| Supernus Pharmaceuticals, INC. | $336.25 | 2022-2025 | Qelbree, Qelbree |
| Lundbeck LLC | $326.34 | 2021-2025 | Rexulti |
| Avanir Pharmaceuticals, INC. | $219.50 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $207.38 | 2023-2025 | Uzedy, Austedo Xr |
| Tris Pharma INC | $182.88 | 2023-2024 | Dyanavel Xr |
| Sunovion Pharmaceuticals INC. | $173.61 | 2021-2022 | |
| Almatica Pharma LLC | $137.56 | 2022-2024 | Loreev Xr, Sertraline Hcl |
| Arbor Pharmaceuticals, INC. | $130.47 | 2021 | |
| Currax Pharmaceuticals LLC | $120.71 | 2021-2025 | Contrave |
| Idorsia Pharmaceuticals US INC | $91.53 | 2023-2024 | Quviviq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.46 | 2024-2025 | |
| Tempus Ai, INC | $83.67 | 2024 | |
| Jazz Pharmaceuticals INC. | $57.96 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $52.10 | 2024-2025 | Abilify Maintena, Rejoyn, Rexulti |
| Adlon Therapeutics L.P. | $34.27 | 2021 | |
| Allergan, INC. | $18.77 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michele Novella listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.